Dopamine agonists and prodrugs taken to treat Parkinson’s disease may cause impulse control disorders in over half the patients they are prescribed to.
Scientists have identified novel genes associated with a specific form of schizophrenia, which could potentially aid diagnosis and development of treatments.
According to a large study, individuals with Type 2 diabetes may have an increased risk of being diagnosed with Parkinson’s disease later in life.
In this research article from Journal of Comparative Effectiveness Research, a new network meta-analysis compares lurasidone and brexpiprazole in acute schizophrenia.
In this research article from Pain Management, researchers investigate the effects of pregabalin, gabapentin and gastroretentive gabapentin on simulated driving performance.
This research article from Neurodegenerative Disease Management investigates how age and disease duration affects Parkinson’s treatment outcome with levodopa-carbidopa intestinal gel.